Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court
This article was originally published in The Pink Sheet Daily
Executive Summary
A mandated price cut for imatinib goes against "fairness" and the purpose of the EU free trade agreement, the court said.
You may also be interested in...
Seoul Court Overturns Health Ministry's 14-Percent Price Cut On Novartis' Glivec
SEOUL - Seoul's Administrative Court ruled in favor of Novartis and suspended the Korean health ministry's plan to cut the price of the Swiss-based company's leukemia drug Glivec (imatinib) by 14 percent beginning Sept. 15
Roche Hits A Wall With Its Tarceva Patent Claims In India; Novartis Moves Supreme Court For Glivec Rights
MUMBAI - For the two Swiss drug giants Novartis and Roche, there was much action at India's Supreme Court Aug. 28 as they separately continued the fight to safeguard patents on their life-saving oncology drugs steadfastly challenged by health activists and generic drug manufacturers alike in India
Korea-EU Free Trade Agreement Creates Another Threat To Local Korean Pharmas; Good For MNCs
SEOUL - The conclusion of the Free Trade Agreement talks on July 13 with the European Union could deal another blow to generic-dependent local South Korean pharma companies, already hit by a similar pact pending with the U.S